Our Company was originally incorporated as 'Anlon Ventures Private Limited', a private limited company under the erstwhile Companies Act, 1956, pursuant to a certificate of incorporation dated November 19, 2013 issued by the RoC. The name of our Company was changed from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited' and a fresh certificate of incorporation dated May 27, 2015 was issued by the RoC pursuant to the approval of the Board on May 1, 2015 and the Shareholders on May 5, 2015. Our Company was subsequently converted to a public limited company and the name of our Company was changed from 'Anlon Healthcare Private Limited' to 'Anlon Healthcare Limited' pursruant to the approval of the Board dated July 8, 2024 and Shareholders August 3, 2024 and a fresh certificate of incorporation dated September 2, 2024 was issued by the RoC.
Our Company was incorporated in the year 2013 as 'Anlon Ventures Private Limited'. In the year 2015, our Company changed its name to Anlon Healthcare Private Limited and decided to establish its own manufacturing facility for manufacturing of pharmaceutical intermediates and APIs. Following this decision, our company began the process of land procurement, construction, and installation of plant and machinery, which were completed in the year 2017. Year 2017 onwards, we started our trial production of pharma intermediates and APIs.
Major Events and Milestones: 2013 - Incorporated as 'Anlon Ventures Private Limited'
2015 - Change of name from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited'.
2017 - Received ISO 9001:2015 certification
2018 - Commenced commercial Production of Pharma Intermediate and API
2018 - Made our first export of our product to South Korea
2019 - Received Good Manufacturing Practice certification for our Manufacturing Facility - Received accreditation of Foreign Manufacturer from Pharmaceuticals and Medical Devices Agency, Japan
2021 - Received Good Manufacturing Practice - World Health Organization Certification for our Manufacturing Facility
2024 - Received approval for Drug Master File from Brazilian Health Regulatory Agency for our API product namely, loxoprofen sodium dihydrate - Conversion of our Company from private limited to public limited and the consequent change of name from 'Anlon Healthcare Private Limited' to 'Anlon Healthcare Limited'.
2025 -The Company has entered into a Share Purchase Agreement between the Anlon Healthcare Limited and Apiqo Organics Private Limited.
|